On Tuesday, Viridian Therapeutics Inc (NASDAQ: VRDN) was 7.80% up from the session before settling in for the closing price of $12.82. A 52-week range for VRDN has been $9.90 – $27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -4.11%. When this article was written, the company’s average yearly earnings per share was at -8.15%. With a float of $73.61 million, this company’s outstanding shares have now reached $81.59 million.
The extent of productivity of a business whose workforce counts for 143 workers is very important to gauge. In terms of profitability, gross margin is -1858.28%, operating margin of -111591.06%, and the pretax margin is -102092.38%.
Viridian Therapeutics Inc (VRDN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viridian Therapeutics Inc stocks. The insider ownership of Viridian Therapeutics Inc is 9.78%, while institutional ownership is 103.42%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.32% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
You can see what Viridian Therapeutics Inc (VRDN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 19.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3758.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.05, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
The latest stats from [Viridian Therapeutics Inc, VRDN] show that its last 5-days average volume of 0.74 million was inferior to 0.99 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 67.19%. Additionally, its Average True Range was 0.87.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 33.56%, which indicates a significant decrease from 83.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.51% in the past 14 days, which was higher than the 58.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.54, while its 200-day Moving Average is $17.87. Now, the first resistance to watch is $14.43. This is followed by the second major resistance level at $15.05. The third major resistance level sits at $15.87. If the price goes on to break the first support level at $13.00, it is likely to go to the next support level at $12.18. Assuming the price breaks the second support level, the third support level stands at $11.57.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are 81,592K outstanding shares of the company, which has a market capitalization of 1.13 billion. As of now, sales total 300 K while income totals -269,950 K. Its latest quarter income was 70 K while its last quarter net income were -86,910 K.
